Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.

被引：8

作者：

Makker, Vicky

Recio, Fernando O.

Ma, Ling

Matutonis, Ursula

Lauchle, Jennifer O'Hara

Parmar, Hema

Gilbert, Houston

Wang, Yulei

Koeppen, Hartmut

Spoerke, Jill M.

Lackner, Mark

Aghajanian, Carol

机构：

[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[2] South Florida Ctr Gynecol Oncol, Boca Raton, FL USA

[3] Rocky Mt Canc Ctr, Lakewood, CO USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Genentech Inc, San Francisco, CA 94080 USA

来源：

关键词：

D O I：

10.1200/jco.2014.32.15_suppl.5513

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5513

引用

页数：1